Company news

Viridian Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)

February 26, 2024

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

February 15, 2024

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

January 16, 2024

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

January 7, 2024

Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease

December 17, 2023

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference

November 20, 2023

Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference

November 7, 2023

Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology

November 2, 2023

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing

October 29, 2023

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease

October 25, 2023

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

September 24, 2023

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September

September 6, 2023

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 7, 2023

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 3, 2023

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

July 9, 2023

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

June 12, 2023

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

May 7, 2023

Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023

May 1, 2023

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

April 19, 2023

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer

April 11, 2023

Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

March 7, 2023

Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

March 6, 2023

Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

February 28, 2023

Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference

February 27, 2023

Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

February 6, 2023

Viridian Appoints Scott Myers as President and Chief Executive Officer

February 5, 2023

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)

January 7, 2023

Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease

December 20, 2022

Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

November 27, 2022

Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

November 13, 2022

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

November 13, 2022

Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022

November 7, 2022

Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th

November 7, 2022

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

October 21, 2022

Viridian Therapeutics Announces Presentations at the American Thyroid Association 91st Annual Meeting

October 11, 2022

Viridian Therapeutics Announces Exercise in Full and Closing of Underwriters’ Option to Purchase Additional Shares in Public Offering

August 24, 2022

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

August 14, 2022

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

August 14, 2022

Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

August 7, 2022

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2022

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

June 22, 2022

Viridian Therapeutics to Participate in June Investor Conferences

May 31, 2022

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

May 11, 2022

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

May 2, 2022

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

April 5, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.